alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 1.168A-6 Depreciation of portion of emergency facility not subject to amortization. ( a ) The rule that an amortization deduction with respect to an emergency facility is in lieu of any deduction for depreciation which would otherwise be allowable under section 167 is subject to the exception provided in section 168(f). Under this exception, if the property constituting such facility is depreciable property under section 167 and the regulations thereunder and if the adjusted basis of such facility as computed under section 1011 for purposes other than the amortization deductions is in excess of the adjusted basis computed for the purpose of the amortization deductions, then the excess shall be charged off over the useful life of the facility and recovered through depreciation deductions. Thus, if the construction of an emergency facility is begun on or before December 31, 1949, and completed after such date, no amortization deductions are allowable with respect to the amount attributable to such construction on or before such date (see § 1.168A-5). However, if the property constituting such facility is depreciable property under section 167 and the regulations thereunder, then the depreciation deduction provided by such section and regulations is allowable with respect to the amount attributable to such construction on or before December 31, 1949.
( b ) Similarly, if only a portion of the construction, reconstruction, erection, installation, or acquisition after December 31, 1949, of an emergency facility has been certified by the certifying authority, and if such facility is depreciable property under section 167 and the regulations thereunder, then the depreciation deduction provided by such section and regulations is allowable with respect to the portion which has not been so certified.
( c ) For illustration of the treatment of a depreciable portion of an emergency facility, see example (2) in paragraph (a)(6) of § 1.168A-5.
[T.D. 6500, 25 FR 11402, Nov. 26, 1960; 25 FR 14021, Dec. 21, 1960. Redesignated and amended by T.D. 8116, 51 FR 46619, Dec. 24, 1986]
Exhibit 32.2

                          CERTIFICATION PURSUANT TO
                           18 U.S.C. SECTION 1350,
                            AS ADOPTED PURSUANT TO
                SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 In connection with the Quarterly Report of American HealthChoice, Inc.  (the
 "Company") on Form 10-QSB for the period ending March 31, 2004 as filed with
 the Securities and Exchange Commission on the date hereof (the "Report"), I,
 John C. Stuecheli, Chief Financial Officer of the Company, certify, pursuant
 to 18 U.S.C. S 1350, as adopted pursuant to S 906 of the Sarbanes-Oxley  Act
 of 2002, that to the best of my knowledge and belief:

           (1)  The Report fully  complies with the  requirements of  Section
           13(a) or 15(d) of the Securities Exchange Act of 1934; and

           (2)  The information contained in  the Report fairly presents,  in
           all material  respects,  the  financial condition  and  result  of
           operations of the Company.



 /s/ John C. Stuecheli


 John C. Stuecheli
 Chief Financial Officer

 May 17, 2004
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 759 Introduced in House (IH)]

<DOC>

118th CONGRESS
  1st Session
                                H. R. 759

 To limit the authority of the Secretary of the Treasury to authorize 
   United States financial institutions to engage in certain Russian-
                      related energy transactions.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            February 2, 2023

   Mr. Barr introduced the following bill; which was referred to the 
                    Committee on Financial Services

_______________________________________________________________________

                                 A BILL

 
 To limit the authority of the Secretary of the Treasury to authorize 
   United States financial institutions to engage in certain Russian-
                      related energy transactions.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``No Energy Revenues for Russian 
Hostilities Act of 2023''.

SEC. 2. LIMITATION ON AUTHORIZING CERTAIN RUSSIAN-RELATED ENERGY 
              TRANSACTIONS.

    (a) In General.--The Secretary of the Treasury may not authorize, 
or continue in effect any existing authorization for, a United States 
financial institution to engage in a transaction described under 
General License No. 8E, dated December 15, 2022, with respect to 
Executive Order 14024 of April 15, 2021.
    (b) Waiver.--The Secretary may waive subsection (a) for up to 90 
days at a time for a United States financial institution upon 
certifying to the Committee on Financial Services of the House of 
Representatives and the Committee on Banking, Housing, and Urban 
Affairs of the Senate that--
            (1) the waiver is only applicable to transactions that 
        involve funds owed to a Russian person; and
            (2) the funds, subject to approval by the Secretary, are to 
        be used for the sale of agricultural commodities, food, 
        medicine, or medical devices.
    (c) Termination.--Subsection (a) shall have no force or effect on 
the earlier of--
            (1) the date that is 5 years after the date of enactment of 
        this Act; or
            (2) 30 days after the date that the President reports to 
        Congress that the Government of the Russian Federation has 
        ceased its destabilizing activities with respect to the 
        sovereignty and territorial integrity of Ukraine.
                                 <all>
```
# C_2015429EN.01001802.xml

| 21.12.2015 | EN | Official Journal of the European Union | C 429/18 |
| --- | --- | --- | --- |

21.12.2015

EN

Official Journal of the European Union

C 429/18

---

Judgment of the General Court of 29 October 2015 — NetMed v OHIM — Sander chemisch-pharmazeutische Fabrik (SANDTER 1953)

(Case T-21/14) (1)

1

((Community trade mark - Opposition proceedings - Application for Community word mark SANDTER 1953 - Earlier national word mark Sander - Relative ground for refusal - Partial refusal of registration - Proof of genuine use of the earlier mark - Article 42(2) and (3) of Regulation (EC) No 207/2009 - Likelihood of confusion - Article 8(1)(b) of Regulation No 207/2009))

(2015/C 429/24)

Language of the case: German

Parties

Parties

Applicant: NetMed Sàrl (Wasserbillig, Luxembourg) (represented by: S. Schafhaus, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: M. Fischer, acting as Agent)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM: Sander chemisch-pharmazeutische Fabrik GmbH (Baden-Baden, Germany)

Other party to the proceedings before the Board of Appeal of OHIM:

Re:

Re:

Action brought against the decision of the First Board of Appeal of OHIM of 24 October 2013 (Case R 1846/2012-1) relating to opposition proceedings between NetMed Sàrl and Sander chemisch-pharmazeutische Fabrik GmbH.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders NetMed Sàrl to pay the costs. |
| --- | --- |

2.

Orders NetMed Sàrl to pay the costs.

---

(1)  OJ C 61, 1.3.2014.

1

---
#### Alfred W. Burkhart, Administrator (Estate oe Diane B. Riley) *v.*Lewis K. Riley, Jr., Executor (Estate oe Nancy H. Riley) Barbara Ann Sanders et al. *v.*Lewis K. Riley, Jr., Executor (Estate of Nancy H. Riley)

*Robert A. Fuller,*for the appellee (plaintiff) in the first case.

*Peter G. Schwartz,*for the appellees (plaintiffs) in the second case.

*Frcmk Smith,*with whom was *Edward M. Sheehy,*for the appellant (defendant) in each ease.

Argued January 7

decided January 7, 1969

The motion by the plaintiff in the first case to dismiss the appeal from the Superior Court in Fair-field County is granted.

The motion by the plaintiffs in the second case to dismiss the appeal from the Superior Court in Fair-field County is granted.
<Page>


                                                                   EXHIBIT 10.27

                      SCHEDULE TO INDEMNIFICATION AGREEMENT

       The following is a list of the current directors and senior executive
officers of Genzyme Corporation who are party to an Indemnification Agreement,
the form of which was filed as Exhibit 10.34 to our Form 10-K for 1990:

                         Constantine E. Anagnostopoulos;
                                Mara G. Aspinall;
                                 Mark Bamforth;
                             Douglas A. Berthiaume;
                                 Henry E. Blair;
                              Robert J. Carpenter;
                              Earl M. Collier, Jr.;
                               Charles L. Cooney;
                                Zoltan A. Csimma;
                              Thomas J. DesRosier;
                               Richard H. Douglas;
                                 Victor J. Dzau;
                                David D. Fleming;
                               James A. Geraghty;
                            Elliott D. Hillback, Jr.;
                                Alison F. Lawton;
                                 Evan M. Lebson;
                                  Roger Louis;
                                Connie Mack III;
                                Gail J. Maderis;
                               John M. McPherson;
                               C. Ann Merrifield;
                              Richard A. Moscicki;
                             Donald E. Pogorzelski;
                                 Alan E. Smith;
                               Sandford D. Smith;
                                Henri A. Termeer
                                Peter T. Traynor;
                               Christine van Heek;
                                G. Jan van Heek;
                                Peter Wirth; and
                                Michael S. Wyzga.
I 

118TH CONGRESS 

2D SESSION H. R. 8037 

To continue to fund the IMPROVE initiative through the Eunice Kennedy 

Shriver National Institute of Child Health and Human Development, 

and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 17, 2024 

Ms. UNDERWOOD (for herself, Mr. FITZPATRICK, and Mr. TORRES of New 

York) introduced the following bill; which was referred to the Committee 

on Energy and Commerce 

A BILL 

To continue to fund the IMPROVE initiative through the 

Eunice Kennedy Shriver National Institute of Child 

Health and Human Development, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘NIH Implementing 

5 a Maternal health and PRegnancy Outcomes Vision for 

6 Everyone Act’’ or the ‘‘NIH IMPROVE Act’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 8037 IH

1 SEC. 2. IMPROVE INITIATIVE. 

2 Subpart 7 of part C of title IV of the Public Health 

3 Service Act (42 U.S.C. 281 et seq.) is amended by adding 

4 at the end the following: 

5 ‘‘SEC. 452H. IMPROVE INITIATIVE. 

6 ‘‘(a) IN GENERAL.—The Director of the Institute 

7 shall continue to carry out the IMPROVE initiative (re8 ferred to in this section as the ‘Initiative’) through the 

9 Institute for the following: 

10 ‘‘(1) Advancing research to— 

11 ‘‘(A) reduce preventable causes of maternal 

12 mortality and severe maternal morbidity; 

13 ‘‘(B) reduce racial, ethnic, geographic, and 

14 socioeconomic disparities in maternal health 

15 outcomes; and 

16 ‘‘(C) improve health for pregnant and 

17 postpartum individuals before, during, and after 

18 pregnancy. 

19 ‘‘(2) Using an integrated approach to under20 stand the biological, behavioral, sociocultural, and 

21 structural factors that affect maternal mortality and 

22 severe maternal morbidity by building an evidence 

23 base for improved care and outcomes in specific re24 gions of the United States. 


ssavage on LAPJG3WLY3PROD with BILLS
3 

•HR 8037 IH

1 ‘‘(3) Targeting health disparities associated 

2 with maternal mortality and severe maternal mor3 bidity by— 

4 ‘‘(A) implementing and evaluating commu5 nity-based interventions for disproportionately 

6 affected individuals; and 

7 ‘‘(B) identifying risk factors and the un8 derlying biological mechanisms associated with 

9 leading causes of maternal mortality and severe 

10 maternal morbidity in the United States, in11 cluding cardiovascular disease, infection and 

12 immunity, vitamin and nutrient deficiencies, 

13 and mental and behavioral health. 

14 ‘‘(b) IMPLEMENTATION.—The Director of the Insti15 tute may award grants or enter into contracts, cooperative 

16 agreements, or other transactions to carry out subsection 

17 (a), including with researchers from racial and ethnic mi18 nority groups (as defined in section 1707(g)(1)). 

19 ‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—There 

20 is authorized to be appropriated to carry out this section 

21 $53,400,000 for each of fiscal years 2025 through 2031.’’. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
**EXHIBIT 32.2**

 

**CERTIFICATION OF PRINCIPALFINANCIAL OFFICERPURSUANT TO 18 U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THESARBANES-OXLEY ACT OF 2002**

 

Inconnection with EMRISECorporation’s (the “Company”) Quarterly Report on Form 10-Qfor the period ended September 30, 2010, as filed with the U.S. Securitiesand Exchange Commission on the date hereof (the “Report”), the undersignedhereby certifies in her capacity as Principal Financial Officer, pursuant to18 U.S.C. section 1350, as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002, that based on her knowledge:

 

1.             the Report fully complies with therequirements of Section 13(a) or 15(d) of the SecuritiesExchange Act of 1934, as amended; and

 

2.             the information contained in theReport fairly presents, in all material respects, the financial condition andresults of operations of the Company.

 
| Dated: November 15, 2010 | By:    | /s/ BRANDI L. FESTA                    |
|-------------------------------|--------|----------------------------------------|
|                          |   | Brandi L. Festa                        |
|                          |   | Director of Finance and Administration |
|                          |   | (Principal Financial Officer)          |

 

 

*A signed original of this written statement required bySection 906, or other document authenticating, acknowledging, or otherwiseadopting the signature that appears in typed form within the electronic versionof this written statement required by Section 906, has been provided tothe Company and will be retained by the Company and furnished to the U.S.Securities and Exchange Commission or its staff upon request.*

 

----
<PAGE>

EXHIBIT 31


                                 CERTIFICATIONS

I, Carmine T. Oliva, certify that:

1.   I have reviewed this amendment no. 1 to Form 10-Q of Emrise Corporation;

2.   Based on my knowledge, this report does not contain any untrue statement of
     a material fact or omit to state a material fact necessary to make the
     statements made, in light of the circumstances under which such statements
     were made, not misleading with respect to the period covered by this
     report; and

3.   Based on my knowledge, the financial statements, and other financial
     information included in this report, fairly present in all material
     respects the financial condition, results of operations and cash flows of
     the registrant as of, and for, the periods presented in this report.

Date: June 13, 2005


/S/ CARMINE T. OLIVA
-----------------------------
Carmine T. Oliva
Chief Executive Officer
(principal executive officer)


<PAGE>

I, Carmine T. Oliva, certify that:

1.   I have reviewed this amendment no. 1 to Form 10-Q of Emrise Corporation;

2.   Based on my knowledge, this report does not contain any untrue statement of
     a material fact or omit to state a material fact necessary to make the
     statements made, in light of the circumstances under which such statements
     were made, not misleading with respect to the period covered by this
     report; and

3.   Based on my knowledge, the financial statements, and other financial
     information included in this report, fairly present in all material
     respects the financial condition, results of operations and cash flows of
     the registrant as of, and for, the periods presented in this report.

Date: June 13, 2005


/S/ CARMINE T. OLIVA
------------------------------
Carmine T. Oliva
Acting Chief Financial Officer
(principal financial officer)
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5530 Flexible laryngoscope. ( a ) *Identification.* A flexible laryngoscope is a fiberoptic device used to examine and visualize a patient's upper airway and aid placement of a tracheal tube.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9.
[47 FR 41107, Sept. 17, 1982, as amended at 61 FR 1120, Jan. 16, 1996; 66 FR 38795, July 25, 2001]
#### § 1.142-3 Refunding Issues. [Reserved]
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.1810 Tangent screen (campimeter). ( a ) *Identification.* A tangent screen (campimeter) is an AC-powered or battery-powered device that is a large square cloth chart with a central mark of fixation intended to map on a flat surface the central 30 degrees of a patient's visual field. This generic type of device includes projection tangent screens, target tangent screens and targets, felt tangent screens, and stereo campimeters.
( b ) *Classification.* Class I (general controls). The AC-powered device and the battery-powered device are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 886.9. The battery-powered device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[55 FR 48442, Nov. 20, 1990, as amended at 59 FR 63013, Dec. 7, 1994; 66 FR 38812, July 25, 2001]
NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

 FOR THE NINTH CIRCUIT

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

 v.

LORENZO GONZALEZ, a.k.a. Grumpy,

Defendant-Appellant.

No. 15-50478

D.C. No. 2:11-cr-00050-SVW

MEMORANDUM*

Appeal from the United States District Court

for the Central District of California

Stephen V. Wilson, District Judge, Presiding

Submitted January 18, 2017** 

Before: TROTT, TASHIMA, and CALLAHAN, Circuit Judges. 

Lorenzo Gonzalez appeals from the district court’s judgment and challenges

the 262-month sentence imposed upon resentencing after remand following his

jury-trial conviction for one count of racketeering influenced and corrupt

organizations conspiracy, in violation of 18 U.S.C. § 1962(d), and two counts of

FILED

JAN 24 2017

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS

* This disposition is not appropriate for publication and is not precedent

except as provided by Ninth Circuit Rule 36-3.

** The panel unanimously concludes this case is suitable for decision

without oral argument. See Fed. R. App. P. 34(a)(2).
violent crime in aid of racketeering in violation of 18 U.S.C. § 1959(a)(2). We

have jurisdiction under 28 U.S.C. § 1291, and we affirm.

Gonzalez contends that his sentence is unreasonable because the district

court declined to impose the below-guidelines sentence recommended by the

probation officer. The record reflects that the district court adequately explained

its reasons for not accepting the probation officer’s recommendation. See United

States v. Carty, 520 F.3d 984, 992 (9th Cir. 2008) (en banc). The district court did

not abuse its discretion in imposing Gonzalez’s sentence. See Gall v. United

States, 552 U.S. 38, 51 (2007). The within-Guidelines sentence is substantively

reasonable in light of the 18 U.S.C. § 3553(a) sentencing factors and the totality of

the circumstances, including the seriousness of Gonzalez’s offenses and the need

for deterrence. See Gall, 552 U.S. at 51.

AFFIRMED. 

2 15-50478
Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
Pursuant to 18 U.S.C. Section 1350, as adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

The undersigned, Kevin S. Herrmann, Chief Financial Officer of Ballantyne Strong, Inc. (the "Company"), has executed this
certification in connection with the filing with the Securities and Exchange Commission of the Company's Annual Report on Form 10-K/A for the year ended December 31, 2010
(the "Report").

The
undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to his knowledge
that:



IN
WITNESS WHEREOF, the undersigned has executed this certification as of the 23rd day of June, 2011.

/s/ KEVIN S. HERRMANN Kevin S. Herrmann
Chief Financial Officer


A
signed original of this written statement required by Section 906 has been provided to Ballantyne Strong, Inc. and will be retained by Ballantyne Strong, Inc. and furnished to
the Securities and Exchange Commission or its staff upon request.

---



QuickLinks
Editorial Note on Part 890
Editorial Note: Nomenclature changes to part 890 appear at 73 FR 35341, June 23, 2008.

§ 890.5710 Hot or cold disposable pack. ( a ) *Identification.* A hot or cold disposable pack is a device intended for medical purposes that consists of a sealed plastic bag incorporating chemicals that, upon activation, provides hot or cold therapy for body surfaces.
( b ) *Classification.* Class I (general controls). Except when intended for use on infants, the device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 890.9.
[48 FR 53047, Nov. 23, 1963, as amended at 65 FR 2322, Jan. 14, 2000]